tiprankstipranks
Trending News
More News >

Bioxytran Delays 10-K Filing Due to Audit

Story Highlights
Bioxytran Delays 10-K Filing Due to Audit

Bioxytran ( (BIXT) ) has released a notification of late filing.

Bioxytran, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is that the company’s independent registered public accounting firm requires additional time to complete the audit of the financial statements. Bioxytran anticipates filing the report within the fifteen-day grace period allowed under Rule 12b-25 of the Securities Exchange Act of 1934. The company does not expect any significant changes in its financial results from the previous fiscal year. Bioxytran is committed to maintaining compliance and transparency, as evidenced by the notification signed by CEO David Platt.

More about Bioxytran

YTD Price Performance: 79.01%

Average Trading Volume: 289,200

Technical Sentiment Signal: Hold

Current Market Cap: $12.78M

Find detailed analytics on BIXT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App